Oncology

News

BMS swoops on Forbius, snaring another immuno-oncology playe...

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius

News

Blow for Novartis as PD-1 drug spartalizumab flunks trial

Novartis’ hopes of catching up with other companies in immuno-oncology have been dented after PD-1 inhibitor spartalizumab failed a phase 3 trial in skin cancer.

News

DNA strand and Cancer Cell Oncology Research Concept 3D rendering

UK cancer mutation testing firm Biofidelity raises $12m

Cambridge, UK-based Biofidelity has raised $12 million in first-round funding for its cancer diagnosis platform, which can detect mutations quicker than current approaches

News

Latecomer Lilly throws cash at Innovent PD-1 partnership

Eli Lilly has doubled down on its partnership with Chia’s Innovent with a licensing deal for ex-China rights to Tyvyt, their PD-1 inhibitor, which some analysts think may be la

Events

Partner Content

2nd Macrophage-directed Therapies Summit

Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody & Cell Therapy based Approaches for Oncology and Beyond

News

BMS signs $475m cancer immunotherapy deal with Dragonfly

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics.

BMS swoops on Forbius, snaring another immuno-oncology playe...

Blow for Novartis as PD-1 drug spartalizumab flunks trial

UK cancer mutation testing firm Biofidelity raises $12m

Latecomer Lilly throws cash at Innovent PD-1 partnership

2nd Macrophage-directed Therapies Summit

BMS signs $475m cancer immunotherapy deal with Dragonfly

Roche culls myostatin candidate from obesity pipeline

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks